Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Photodynamic therapy proves worth in UK assessment, but more research needed

This article was originally published in Clinica

Executive Summary

Photodynamic therapy (PDT) “shows potential” for the treatment of pre-cancerous skin conditions, Barrett's oesophagus and certain cancers, but its value in comparison with other technologies remains unclear. So concluded a study just published by a team at the UK’s Centre for Reviews and Dissemination, University of York, following a health technology assessment (HTA) commissioned for the NHS. The cancers it considered were of the: biliary tract, brain, head/neck, lung, oesophagus and skin. “PDT showed potential promise...across the conditions and sites investigated. However, its place in relation to other available treatments was unclear and there is a need for further, high quality research in this area,” the team concluded.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel